NICE Recommends SGLT-2 Inhibitors as First-Line Type 2 Diabetes Treatment in UK Guidelines
On February 1, 2026, the UK’s National Institute for Health and Care Excellence (NICE) recommended SGLT-2 inhibitors as first-line therapy for most newly diagnosed type 2 diabetes patients, marking a shift from glucose-centric to organ-protective treatment. NICE guideline change redefines diabetes care priorities The updated guidance positions SGLT-2 inhibitors alongside metformin as initial treatment, expanding … Weiterlesen …